Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil
Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript
Altimmune Q1 Earnings Call Highlights
Altimmune Announces First Quarter 2026 Financial Results and Business Update
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
AI Financial Corporation (Formerly ALT5 Sigma) Begins Trading Under New Nasdaq Ticker Symbol 'AIFC'
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of “Moderate Buy” from Analysts
Altimmune Catalysts: 2026 Data Readouts and Financing Risks
ALT Stock: What Pemvidutide Means for MASH, AUD and ALD
Is Altimmune a Buy Before Phase III MASH Starts in 2026?
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
Altimmune Announces Proposed Underwritten Public Offering of Securities
ALT5 Sigma Corporation Announces Planned Rebrand to AI Financial Corporation (AiFi) and Nasdaq Ticker Change
Altimmune Shareholders Approve All AGM Proposals, Boost Authorized Shares to 400M
ALT5 Sigma Corporation Reports Full Year 2025 Financial Results
Altimmune (NASDAQ:ALT) versus TNF Pharmaceuticals (NASDAQ:TNFA) Head-To-Head Comparison
ALT Stock and the 2026 MASH Race: Dual Agonists vs. New Mechanisms
Altimmune Stock: Neutral Outlook With Big 2026 Catalysts
ALT Pemvidutide Explained: What Makes It Different in MASH
Altimmune: The High Cost Of Going Solo (Rating Downgrade)
Altimmune, Inc. (ALT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Altimmune Q4 Earnings Call Highlights
Altimmune, Inc. (ALT) Q4 2025 Earnings Call Transcript
Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
Altimmune to Participate in Upcoming Investor Conferences
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play
Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
ALT5 Sigma Corporation Issues Stockholder Letter and Provides Corporate Update
ALT5 Sigma Corporation Appoints Dr. Adel Elmessiry to Board of Directors
Altimmune (NASDAQ:ALT) Shares Up 7.2% – Time to Buy?
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
Altimmune (ALT) Shares Slide On $75 Million Stock Offering
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock
ALT5 Sigma Corporation to Join Global Leaders at Inaugural World Liberty Forum at Mar-a-Lago
Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly
ALT5 Sigma Corporation Launches ALT5 AI to Power the Next Era of Enterprise AI—Where Crypto, Compliance and AI Payment Rails Converge
ALT5 Sigma Corporation Restores Compliance with Nasdaq Periodic Filing Requirements
ALT5 Sigma Corporation Reports Q3 2025 Financial Results and Significant Milestones
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH
ALT5 Sigma Expects to File its Quarterly Report on Form 10-Q for the Third Quarter 2025 in the Coming Days
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
ALT5 Sigma Congratulates Strategic Partner World Liberty Financial on USD1 Stablecoin Surpassing $3 Billion Market Capitalization
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround
ALT5 INVESTIGATION: Investigation Launched into ALT5 Sigma Corporation, Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - ALTS
Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen
Altimmune (NASDAQ:ALT) Director Jerome Benedict Durso Acquires 12,500 Shares of Stock